Obesity – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
Obesity Market
Outlook
Thelansis’s “Obesity Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026
To 2036” covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Obesity
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
Obesity Overview
Obesity is a complex, chronic,
neurobehavioral disease characterized by excessive accumulation of body fat
that impairs health and elevates the risk of comorbidities like type 2
diabetes, cardiovascular disease, and certain cancers. Rather than a simple calorie
imbalance, it is driven by dysregulation of neuroendocrine pathways controlling
energy homeostasis and appetite. Diagnosis historically relies on a body mass
index of 30 or higher, though clinical focus in 2026 prioritizes staging based
on adiposity-associated complications and visceral distribution. Management
requires a multi-component strategy combining nutritional optimization,
behavioral therapy, and physical activity with highly effective long-term
medical interventions. Second-generation anti-obesity medications, particularly
multi-incretin receptor agonists targeting GLP-1, GIP, or glucagon pathways,
serve as standard frontline pharmacotherapy to achieve sustained metabolic
restoration, with bariatric surgery reserved for severe or refractory cases.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by robust research, including:
- In-depth interviews with leading KOLs
and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based
automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2025–2035)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g.,
drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the most
promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment